Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 20/20 | 0.82 |
| ▸ | MAPK9 | P45984 | 15/20 | 0.82 |
| ▸ | MAPK10 | P53779 | 15/20 | 0.82 |
| ▸ | CIT | O14578 | 1/20 | 0.80 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.80 |
| ▸ | STK16 | O75716 | 1/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.80 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.80 |
| ▸ | CDK11B | P21127 | 1/20 | 0.80 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | MAPK4 | P31152 | 1/20 | 0.80 |
| ▸ | TTK | P33981 | 1/20 | 0.80 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.80 |
| ▸ | GSK3A | P49840 | 1/20 | 0.80 |
| ▸ | GSK3B | P49841 | 1/20 | 0.80 |
| ▸ | CDK7 | P50613 | 1/20 | 0.80 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.80 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.80 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093818 | 1.00 | MAPK8 (0.82) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL7979990 | 1.00 | MAPK8 (0.82) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL14175955 | 0.93 | MAPK8 (0.81) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL14768196 | 0.93 | MAPK8 (0.81) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL14834313 | 0.93 | MAPK8 (0.81) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL6764829 | 0.93 | MAPK8 (0.81) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL14834426 | 0.92 | MAPK8 (0.80) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL14176043 | 0.92 | MAPK8 (0.80) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL5102616 | 0.92 | MAPK8 (0.79) | MAPK8MAPK9MAPK10CITDAPK3 | |
| SCHEMBL5090230 | 0.92 | MAPK8 (0.70) | MAPK8MAPK9MAPK10CITDAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576537-B1 | 2-AMINO-PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2016-03-16 | — | — | EP | disclosed |
| EP-2576559-B1 | INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-8642601-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8183254-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183254-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2012-05-22 | — | — | US | disclosed |
| WO-2011151358-A1 | 2 -AMINO- PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
| US-20110301170-A1 | Inhibitors of JNK | GONG LEYI (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301171-A1 | Inhibitors of JNK | ARZENO HUMBERTO BARTOLOME (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011151357-A1 | INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
| US-20090318484-A1 | Inhibitors of JNK | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318484-A1 | Inhibitors of JNK | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | MAPK8 40/4885MAPK9 43/4885MAPK10 31/4885 |
| US-20090318484-A1 | Inhibitors of JNK | MAPK1, MAP3K6, MAP3K1 | MAPK8 36/4885MAPK9 30/4885MAPK10 54/4885 |
| US-20110301170-A1 | Inhibitors of JNK | MAPK6, MAP3K6, MAPK1 | MAPK8 35/4885MAPK9 11/4885MAPK10 29/4885 |
| US-20110301171-A1 | Inhibitors of JNK | MAPK9, MAP3K9, MAPK1 | MAPK8 28/4885MAPK9 1/4885MAPK10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.